Renal association clinical practice guideline in post-operative care in the kidney transplant recipient

Richard J Baker, Patrick B Mark, Rajan K Patel, Kate K Stevens, Nicholas Palmer, Richard J Baker, Patrick B Mark, Rajan K Patel, Kate K Stevens, Nicholas Palmer

Abstract

These guidelines cover the care of patients from the period following kidney transplantation until the transplant is no longer working or the patient dies. During the early phase prevention of acute rejection and infection are the priority. After around 3-6 months, the priorities change to preservation of transplant function and avoiding the long-term complications of immunosuppressive medication (the medication used to suppress the immune system to prevent rejection). The topics discussed include organization of outpatient follow up, immunosuppressive medication, treatment of acute and chronic rejection, and prevention of complications. The potential complications discussed include heart disease, infection, cancer, bone disease and blood disorders. There is also a section on contraception and reproductive issues.Immediately after the introduction there is a statement of all the recommendations. These recommendations are written in a language that we think should be understandable by many patients, relatives, carers and other interested people. Consequently we have not reworded or restated them in this lay summary. They are graded 1 or 2 depending on the strength of the recommendation by the authors, and AD depending on the quality of the evidence that the recommendation is based on.

References

    1. Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80:1383–91. doi: 10.1097/.
    1. Adamu B, Abdu A, Abba AA, Borodo MM, Tleyjeh IM. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev. 2014;3:CD008597.
    1. Allen U, Preiksaitis J, Practice ASTIDCo Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S87–96. doi: 10.1111/j.1600-6143.2009.02898.x.
    1. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol. 2009;20:2490–2. doi: 10.1681/ASN.2008091005.
    1. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant. 2007;7:2748–56. doi: 10.1111/j.1600-6143.2007.02006.x.
    1. Amer H, Lieske JC, Rule AD, et al. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant. 2013;13:676–84. doi: 10.1111/ajt.12044.
    1. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241–8. doi: 10.1002/ajmg.a.32685.
    1. Armenti VT, Daller JA, Constantinescu S, et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clinical transplants. 2006:57–70.
    1. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9:1205–13. doi: 10.1111/j.1600-6143.2009.02617.x.
    1. Beimler J, Zeier M. Borderline rejection after renal transplantation--to treat or not to treat. Clin Transpl. 2009;23(Suppl 21):19–25. doi: 10.1111/j.1399-0012.2009.01105.x.
    1. Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation. 2008;86:413–7. doi: 10.1097/TP.0b013e31817c13e1.
    1. Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65. doi: 10.1016/S0140-6736(14)60892-8.
    1. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471–9. doi: 10.1002/jbmr.1613.
    1. Board JBS Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart. 2014;100(Suppl 2):ii1–67. doi: 10.1136/heartjnl-2014-305693.
    1. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol. 2007;2(Suppl 1):S36–46. doi: 10.2215/CJN.00920207.
    1. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002;13:1091–9.
    1. Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, von Eckardstein A, Graf N, Wüthrich RP. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882–91. doi: 10.1111/ajt.13692.
    1. Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant. 2007;7:2515–21. doi: 10.1111/j.1600-6143.2007.01950.x.
    1. Bramham K, Nelson-Piercy C, Gao H, et al. Pregnancy in renal transplant recipients: a UK national cohort study. Clin J Am Soc Nephrol. 2013;8:290–8. doi: 10.2215/CJN.06170612.
    1. Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol. 2013;8:563–7. doi: 10.2215/CJN.06400612.
    1. Brokhof MM, Sollinger HW, Hager DR, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation. 2014;97:612–7. doi: 10.1097/TP.0000000000000031.
    1. BSHI/BTS . Guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. 2014.
    1. BTS . Management of the Failing Kidney Transplant. 2013.
    1. BTS . Antibody Incompatible Transplantation Guideline. 2015.
    1. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant. 2006;6:770–4. doi: 10.1111/j.1600-6143.2006.01263.x.
    1. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377:837–47. doi: 10.1016/S0140-6736(10)62318-5.
    1. Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119–28. doi: 10.1111/ajt.12952.
    1. Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant. 2004;19:3144–9. doi: 10.1093/ndt/gfh505.
    1. Carpenter MA, Weir MR, Adey DB, House AA. Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transpl. 2012;26:E438–46. doi: 10.1111/j.1399-0012.2012.01676.x.
    1. Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. Transplantation. 2011;92:774–80. doi: 10.1097/TP.0b013e31822ca7ca.
    1. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289–93. doi: 10.1097/01.TP.0000100826.58738.2B.
    1. Cherukuri A, Welberry-Smith MP, Tattersall JE, et al. The clinical significance of early proteinuria after renal transplantation. Transplantation. 2010;89:200–7. doi: 10.1097/TP.0b013e3181c352c5.
    1. Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol. 2012;7:504–12. doi: 10.2215/CJN.06940711.
    1. Choukroun G, Kamar N, Dussol B, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360–8. doi: 10.1681/ASN.2011060546.
    1. Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis. 2009;49:1550–6. doi: 10.1086/644734.
    1. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360:2683–5. doi: 10.1056/NEJMc0808481.
    1. Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int. 2006;70:1367–70. doi: 10.1038/sj.ki.5001833.
    1. Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis. 2014;63:A7. doi: 10.1053/j.ajkd.2013.11.001.
    1. Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol. 1997;8:1930–41.
    1. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82–8. doi: 10.1038/nrrheum.2009.259.
    1. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65–85.
    1. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation. 2010;90:695–704. doi: 10.1097/TP.0b013e3181ecea8d.
    1. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S68–75. doi: 10.2215/CJN.02770707.
    1. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation. 1999;68:1859–64. doi: 10.1097/00007890-199912270-00008.
    1. de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol. 2001;12:1538–46.
    1. Dharnidharka VR, Cherikh WS, Neff R, Cheng Y, Abbott KC. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant. 2010;10:1312–5. doi: 10.1111/j.1600-6143.2010.03083.x.
    1. Do H. Achieving Excellence in Kidney Care: Delivering the National Service Framework for Renal Services. 2009.
    1. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4:2082–92. doi: 10.1046/j.1600-6143.2004.00603.x.
    1. Drueke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s) Kidney Int. 2012;82:952–60. doi: 10.1038/ki.2012.270.
    1. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” study. Transplantation. 2005;79:466–75. doi: 10.1097/01.TP.0000151632.21551.00.
    1. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. The Cochrane database of systematic reviews. 2007:CD004659.
    1. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–44. doi: 10.1503/cmaj.070256.
    1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–75. doi: 10.1056/NEJMoa067411.
    1. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9:1876–85. doi: 10.1111/j.1600-6143.2009.02726.x.
    1. Elder GJ. From marrow oedema to osteonecrosis: common paths in the development of post-transplant bone pain. Nephrology. 2006;11:560–7. doi: 10.1111/j.1440-1797.2006.00708.x.
    1. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527–35. doi: 10.1111/j.1600-6143.2008.02519.x.
    1. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329–39. doi: 10.1056/NEJMoa1204166.
    1. Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. Am J Kidney Dis. 2003;41:493–6. doi: 10.1053/ajkd.2003.50061.
    1. Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant. 2005;20:1714–20. doi: 10.1093/ndt/gfh892.
    1. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95:410–7. doi: 10.1097/TP.0b013e31827d62e3.
    1. Excellence NIfC . Hypertension in pregnancy: The management of hypertensive disorders during pregnancy (clinical guideline 107) 2010.
    1. Filocamo MT, Zanazzi M, Li Marzi V, et al. Sexual dysfunction in women during dialysis and after renal transplantation. J Sex Med. 2009;6:3125–31. doi: 10.1111/j.1743-6109.2009.01400.x.
    1. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89:255–74. doi: 10.1016/0002-9343(90)90337-D.
    1. Garg S, Carroll RP, Walker RG, Ramsay HM, Harden PN. Skin cancer surveillance in renal transplant recipients: re-evaluation of U.K. practice and comparison with Australian experience. Br J Dermatol. 2009;160:177–9. doi: 10.1111/j.1365-2133.2008.08837.x.
    1. Gaynor JJ, Ciancio G, Guerra G, et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int. 2016;29:216–26. doi: 10.1111/tri.12699.
    1. Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ. Oral versus intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not? Lancet. 1978;1:117–8. doi: 10.1016/S0140-6736(78)90417-8.
    1. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052–9. doi: 10.4065/82.9.1052.
    1. Grinyo JM, Saval N, Campistol JM, Group IS. Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients. Nephrol Dial Transplant. 2011;26:3750–5. doi: 10.1093/ndt/gfr091.
    1. Grotz WH, Breitenfeldt MK, Braune SW, et al. Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation. Transpl Int. 2001;14:16–23. doi: 10.1111/j.1432-2277.2001.tb00004.x.
    1. Group CSC, Haynes R, Harden P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384:1684–90. doi: 10.1016/S0140-6736(14)61095-3.
    1. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–83. doi: 10.1111/ajt.12590.
    1. Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant. 2005;5:2281–8. doi: 10.1111/j.1600-6143.2005.01020.x.
    1. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364:1909–19. doi: 10.1056/NEJMoa1009546.
    1. Harden PN, Fryer AA, Reece S, Smith AG, Ramsay HM. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients. Transplant Proc. 2001;33:1302–4. doi: 10.1016/S0041-1345(00)02486-6.
    1. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10:407–15. doi: 10.1111/j.1600-6143.2009.02952.x.
    1. Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant. 2010;15:35–41. doi: 10.1097/MOT.0b013e3283342728.
    1. Health Information for overseas travel - Department of Health. 2015.
    1. Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365–76. doi: 10.1016/S0140-6736(06)69561-5.
    1. Heiwe S, Jacobson SH. Exercise Training in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2014;64:383–93. doi: 10.1053/j.ajkd.2014.03.020.
    1. Hellemans R, Hazzan M, Durand D, et al. Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study. Am J Transplant. 2015;15:1923–32. doi: 10.1111/ajt.13191.
    1. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9:2532–41. doi: 10.1111/j.1600-6143.2009.02800.x.
    1. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347:488–96. doi: 10.1056/NEJMoa020439.
    1. Hirsch HH, Randhawa P, Practice ASTIDCo BK virus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S136–46. doi: 10.1111/j.1600-6143.2009.02904.x.
    1. Ho J, Wiebe C, Gibson IW, Rush DN, Nickerson PW. Immune monitoring of kidney allografts. Am J Kidney Dis. 2012;60:629–40. doi: 10.1053/j.ajkd.2012.01.028.
    1. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet. 2005;365:2105–15. doi: 10.1016/S0140-6736(05)66553-1.
    1. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024–31. doi: 10.1016/S0140-6736(03)13638-0.
    1. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–36. doi: 10.1111/j.1600-6143.2005.01105.x.
    1. Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A. Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant. 2007;7:1948–53. doi: 10.1111/j.1600-6143.2007.01883.x.
    1. Humar A, Snydman D, Practice ASTIDCo Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S78–86. doi: 10.1111/j.1600-6143.2009.02897.x.
    1. Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant. 2009;9:374–81. doi: 10.1111/j.1600-6143.2008.02501.x.
    1. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228–37. doi: 10.1111/j.1600-6143.2010.03074.x.
    1. Hurst FP, Altieri M, Patel PP, et al. Effect of smoking on kidney transplant outcomes: analysis of the United States Renal Data System. Transplantation. 2011;92:1101–7. doi: 10.1097/TP.0b013e3182336095.
    1. Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis. 2005;46:529–36. doi: 10.1053/j.ajkd.2005.05.014.
    1. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378:1419–27. doi: 10.1016/S0140-6736(11)61334-2.
    1. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89:1057–70. doi: 10.1097/TP.0b013e3181d0e15e.
    1. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004;78:1233–6. doi: 10.1097/01.TP.0000137937.44703.42.
    1. Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251) Cancer. 2012;118:2128–37. doi: 10.1002/cncr.26374.
    1. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72:1181–93. doi: 10.1097/00007890-200110150-00001.
    1. Kahan BD, Welsh M, Urbauer DL, et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol. 2000;11:1122–31.
    1. Kandil E, Florman S, Alabbas H, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci. 2010;339:420–4. doi: 10.1097/MAJ.0b013e3181d8b6ff.
    1. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–9. doi: 10.1097/01.TP.0000184006.43152.8D.
    1. Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d + in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant. 2009;9:812–9. doi: 10.1111/j.1600-6143.2009.02555.x.
    1. Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transpl. 2009;23:800–6. doi: 10.1111/j.1399-0012.2008.00947.x.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.
    1. Kidney Disease: Improving Global Outcomes Transplant Work G KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.
    1. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–25. doi: 10.1111/j.1600-6143.2007.01972.x.
    1. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675–85. doi: 10.1097/TP.0b013e3181744199.
    1. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679. doi: 10.1136/bmj.g6679.
    1. Knoll GA, Fergusson D, Chasse M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2015.
    1. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–60. doi: 10.1097/TP.0b013e31829df29d.
    1. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499–505. doi: 10.1097/00007691-200410000-00007.
    1. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant. 2009;9:1826–34. doi: 10.1111/j.1600-6143.2009.02701.x.
    1. Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13:2411–7. doi: 10.1111/ajt.12329.
    1. Kuypers DR, Bammens B, Claes K, Evenepoel P, Vanrenterghem Y. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. Transplantation. 2010;89:1296–7. doi: 10.1097/TP.0b013e3181d84c66.
    1. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87:1505–13. doi: 10.1097/TP.0b013e3181a44206.
    1. Langone A, Steinberg SM, Gedaly R, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transpl. 2015;29:796–805. doi: 10.1111/ctr.12581.
    1. Lee J, Huh KH, Park Y, et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2015.
    1. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9:1099–107. doi: 10.1111/j.1600-6143.2009.02591.x.
    1. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16:496–506. doi: 10.1681/ASN.2004070580.
    1. Lentine KL, Schnitzler MA, Xiao H, Brennan DC. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants. Trials. 2015;16:365. doi: 10.1186/s13063-015-0891-y.
    1. Lim W, Chadban S, Campbell S, Dent H, Russ G, McDonald S. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transpl Int. 2010;23:1207–15. doi: 10.1111/j.1432-2277.2010.01124.x.
    1. Lo P, Sharma A, Craig JC, et al. Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation. 2015.
    1. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9:231–5. doi: 10.1111/j.1600-6143.2008.02451.x.
    1. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–26. doi: 10.1056/NEJMoa1302506.
    1. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340:1462–70. doi: 10.1056/NEJM199905133401903.
    1. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol. 2009;20:2449–58. doi: 10.1681/ASN.2008111166.
    1. Machnicki G, Pinsky B, Takemoto S, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am J Transplant. 2009;9:494–505. doi: 10.1111/j.1600-6143.2008.02486.x.
    1. Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab as induction therapy in renal transplantation. Transplant Rev. 2015;29:103–8. doi: 10.1016/j.trre.2014.12.001.
    1. Mactier R, Davies S, Dudley C, et al. Summary of the 5th edition of the renal association clinical practice guidelines (2009–2012) Nephron Clin Pract. 2011;118(Suppl 1):c27–70. doi: 10.1159/000328060.
    1. Maggiore U, Medici MC, Vaglio A, Buzio C. Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. Transpl Infect Dis. 2010;12:470–2. doi: 10.1111/j.1399-3062.2010.00512.x.
    1. Malavaud B, Rostaing L, Rischmann P, Sarramon JP, Durand D. High prevalence of erectile dysfunction after renal transplantation. Transplantation. 2000;69:2121–4. doi: 10.1097/00007890-200005270-00027.
    1. Maluf DG, Dumur CI, Suh JL, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int. 2014;85:439–49. doi: 10.1038/ki.2013.338.
    1. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007;7:864–71. doi: 10.1111/j.1600-6143.2006.01711.x.
    1. Massey EK, Tielen M, Laging M, et al. The role of goal cognitions, illness perceptions and treatment beliefs in self-reported adherence after kidney transplantation: a cohort study. J Psychosom Res. 2013;75:229–34. doi: 10.1016/j.jpsychores.2013.07.006.
    1. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.
    1. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant. 2005;5:2473–8. doi: 10.1111/j.1600-6143.2005.01051.x.
    1. Matas AJ, Gillingham K, Kandaswamy R, et al. Kidney transplant half-life (t[1/2]) after rapid discontinuation of prednisone. Transplantation. 2009;87:100–2. doi: 10.1097/TP.0b013e31818c25ab.
    1. Matoza JR, Danguilan RA, Chicano S. Impact of Banff borderline acute rejection among renal allograft recipients. Transplant Proc. 2008;40:2303–6. doi: 10.1016/j.transproceed.2008.07.004.
    1. McKay DB, Josephson MA. Pregnancy in recipients of solid organs--effects on mother and child. N Engl J Med. 2006;354:1281–93. doi: 10.1056/NEJMra050431.
    1. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233–9. doi: 10.1097/01.ASN.0000145435.80005.1E.
    1. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807–18. doi: 10.1034/j.1600-6143.2002.20902.x.
    1. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant. 2005;5:2611–8. doi: 10.1111/j.1600-6143.2005.01086.x.
    1. Morken NH, Diaz-Garcia C, Reisaeter AV, et al. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation. Am J Transplant. 2015;15:1666–73. doi: 10.1111/ajt.13159.
    1. Morrissey PE, Gohh R, Shaffer D, et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation. 1997;63:845–8. doi: 10.1097/00007890-199703270-00009.
    1. Mycophenolate Mofetil Acute Renal Rejection Study G Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation. 2001;71:1091–7. doi: 10.1097/00007890-200104270-00014.
    1. Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men. 2015. at .
    1. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004;78:242–9. doi: 10.1097/.
    1. NHS Cancer Screening Programmes. 2014. at .
    1. Nicholson ML, Wheatley TJ, Doughman TM, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int. 2000;58:390–5. doi: 10.1046/j.1523-1755.2000.00177.x.
    1. Nicoletto BB, Fonseca NK, Manfro RC, Goncalves LF, Leitao CB, Souza GC. Effects of obesity on kidney transplantation outcomes: a systematic review and meta-analysis. Transplantation. 2014;98:167–76. doi: 10.1097/TP.0000000000000028.
    1. Norrman E, Bergh C, Wennerholm UB. Pregnancy outcome and long-term follow-up after in vitro fertilization in women with renal transplantation. Hum Reprod. 2015;30:205–13. doi: 10.1093/humrep/deu293.
    1. Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS). 2011. at .)
    1. O’Grady JG, Asderakis A, Bradley R, et al. Multidisciplinary insights into optimizing adherence after solid organ transplantation. Transplantation. 2010;89:627–32. doi: 10.1097/TP.0b013e3181ca87b0.
    1. Opelz G, Dohler B. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation. 2014;97:310–5. doi: 10.1097/TP.0000000000000139.
    1. Pallet N, Burgard M, Quamouss O, et al. Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation. 2010;89:1542–4. doi: 10.1097/TP.0b013e3181d7212f.
    1. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–24. doi: 10.1378/chest.113.5.1215.
    1. Parker R, Armstrong MJ, Corbett C, Day EJ, Neuberger JM. Alcohol and substance abuse in solid-organ transplant recipients. Transplantation. 2013;96:1015–24. doi: 10.1097/TP.0b013e31829f7579.
    1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–90. doi: 10.1056/NEJMra011295.
    1. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception. 2010;82:102–12. doi: 10.1016/j.contraception.2010.02.007.
    1. Pergam SA, Limaye AP, Practice ASTIDCo Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S108–15. doi: 10.1111/j.1600-6143.2009.02901.x.
    1. Peters B, Andersson Y, Stegmayr B, et al. A study of clinical complications and risk factors in 1,001 native and transplant kidney biopsies in Sweden. Acta Radiol. 2014;55:890–6. doi: 10.1177/0284185113506190.
    1. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32. doi: 10.1056/NEJMoa0907845.
    1. Pilch NA, Taber DJ, Moussa O, et al. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014;259:888–93. doi: 10.1097/SLA.0000000000000496.
    1. Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation. 2011;91:542–51. doi: 10.1097/TP.0b013e31820437bd.
    1. Ponticelli C. Basiliximab: efficacy and safety evaluation in kidney transplantation. Expert Opin Drug Saf. 2014;13:373–81. doi: 10.1517/14740338.2014.861816.
    1. Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol. 2010;5:1305–11. doi: 10.2215/CJN.07241009.
    1. Qureshi F, Rabb H, Kasiske BL. Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. Transplantation. 2002;74:1400–4. doi: 10.1097/00007890-200211270-00010.
    1. Raggi MC, Siebert SB, Friess H, Schremmer-Danninger E, Thorban S, Dinkel A. Sexual and relationship functioning before and after renal transplantation: a descriptive study with patients and partners. Scand J Urol Nephrol. 2012;46:431–6. doi: 10.3109/00365599.2012.693132.
    1. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–30. doi: 10.1097/TP.0b013e318197c17d.
    1. Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation. 2007;84:437–9. doi: 10.1097/01.tp.0000269707.06060.dc.
    1. Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation. 2010;89:1462–5. doi: 10.1097/TP.0b013e3181daaaf1.
    1. Razonable RR, Zerr DM, Practice ASTIDCo HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S97–100. doi: 10.1111/j.1600-6143.2009.02899_1.x.
    1. Reece SM, Harden PN, Smith AG, Ramsay HM. A model for nurse-led skin cancer surveillance following renal transplantation. Nephrol Nurs J. 2002;29:257–9.
    1. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12:1975–82. doi: 10.1111/j.1600-6143.2012.04084.x.
    1. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015;11:98–109. doi: 10.1038/nrrheum.2014.188.
    1. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94:775–83. doi: 10.1097/TP.0b013e31825d1587.
    1. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875–83. doi: 10.1111/ajt.12460.
    1. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3:79–87. doi: 10.1034/j.1399-3062.2001.003002079.x.
    1. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol. 2006;17:305–12. doi: 10.1681/ASN.2005030249.
    1. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7:2538–45. doi: 10.1111/j.1600-6143.2007.01979.x.
    1. SaBTO/BSBMT . Reducing the risk of Transfusion-transmitted Hepatitis E Virus (HEV) infections in patients undergoing Solid Organ Transplantation (SOT) and Haematopoietic Stem Cell Transplantation (HSCT) 2016.
    1. SaBTO/BSBMT . SaBTO Letter to Clinicians - Re Hep E Virus. 2016.
    1. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385–93. doi: 10.1111/j.1600-6143.2009.02997.x.
    1. Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85:1404–11. doi: 10.1038/ki.2013.465.
    1. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–42. doi: 10.1097/TP.0b013e3181927a41.
    1. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–99. doi: 10.1111/j.1600-6143.2011.03840.x.
    1. Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8:803–10. doi: 10.1111/j.1600-6143.2007.02136.x.
    1. Sezai A, Soma M, Nakata KI, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD) J Cardiol. 2015;66(4):289–303. doi: 10.1016/j.jjcc.2014.12.017.
    1. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc. 1999;31:1134. doi: 10.1016/S0041-1345(98)01935-6.
    1. Sharma RK, Prasad N, Gupta A, Kapoor R. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis. 2006;48:128–33. doi: 10.1053/j.ajkd.2006.04.061.
    1. Shehata M, Bhandari S, Venkat-Raman G, et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int. 2009;22:821–30. doi: 10.1111/j.1432-2277.2009.00877.x.
    1. Shinn C, Malhotra D, Chan L, Cosby RL, Shapiro JI. Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Am J Kidney Dis. 1999;34:304–7. doi: 10.1016/S0272-6386(99)70359-8.
    1. Short CD, Russell S, Valentine A. Clinical audit and long-term evaluation of renal transplant recipients. Transplantation. 2001;72:S94–8.
    1. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–702. doi: 10.1097/01.tp.0000252683.74584.29.
    1. Sofue T, Inui M, Hara T, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Drug Des Devel Ther. 2014;8:245–53. doi: 10.2147/DDDT.S56597.
    1. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–60. doi: 10.1111/j.1600-6143.2008.02159.x.
    1. Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellstrom B. A cardiovascular risk calculator for renal transplant recipients. Transplantation. 2012;94:57–62. doi: 10.1097/TP.0b013e3182516cdc.
    1. Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:323–6. doi: 10.2215/CJN.00500705.
    1. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–23. doi: 10.1056/NEJMoa042831.
    1. Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30:642–50.
    1. Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others? Nephrol Dial Transplant. 2001;16:873–4. doi: 10.1093/ndt/16.4.873.
    1. Sun Q, Liu ZH, Yin G, et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant. 2006;21:510–7. doi: 10.1093/ndt/gfk027.
    1. Sun Q, Liu ZH, Cheng Z, et al. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int. 2007;71:24–30. doi: 10.1038/sj.ki.5001870.
    1. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19–47. doi: 10.1097/TP.0b013e31827a19cc.
    1. Tojimbara T, Nakajima I, Yashima J, Fuchinoue S, Teraoka S. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients. Transplant Proc. 2014;46:511–3. doi: 10.1016/j.transproceed.2013.09.045.
    1. Tong A, Howell M, Wong G, Webster AC, Howard K, Craig JC. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant. 2011;26:344–54. doi: 10.1093/ndt/gfq376.
    1. Torres A, Garcia S, Gomez A, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 2004;65:705–12. doi: 10.1111/j.1523-1755.2004.00432.x.
    1. Turk TR, Voropaeva E, Kohnle M, et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008;23:369–73. doi: 10.1093/ndt/gfm620.
    1. Tutone VK, Mark PB, Stewart GA, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transpl. 2005;19:181–92. doi: 10.1111/j.1399-0012.2004.00315.x.
    1. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2006;70:2058–65. doi: 10.1038/sj.ki.5001875.
    1. UK KR . Kidney Health Delivering Excellence. 2013.
    1. van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation. 2010;89:320–6. doi: 10.1097/TP.0b013e3181bc0301.
    1. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant. 2009;9:1495–9. doi: 10.1111/j.1600-6143.2009.02678.x.
    1. van Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int. 2014;85:1267–8. doi: 10.1038/ki.2013.484.
    1. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353:770–81. doi: 10.1056/NEJMoa050085.
    1. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–14. doi: 10.1111/j.1600-6143.2007.01749.x.
    1. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int. 2003;63:1187–94. doi: 10.1046/j.1523-1755.2003.00850.x.
    1. Wadei HM, Textor SC. Hypertension in the kidney transplant recipient. Transplant Rev (Orlando) 2010;24(3):105–20. doi: 10.1016/j.trre.2010.02.001.
    1. Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;12:CD007746.
    1. Watnick S, Rueda J. Reproduction and contraception after kidney transplantation. Curr Opin Obstet Gynecol. 2008;20:308–12. doi: 10.1097/GCO.0b013e3282f8b009.
    1. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810. doi: 10.1136/.
    1. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234–48. doi: 10.1097/01.tp.0000219703.39149.85.
    1. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81:953–65. doi: 10.1097/01.tp.0000215178.72344.9d.
    1. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011;79:897–907. doi: 10.1038/ki.2010.492.
    1. Welberry Smith MP, Cherukuri A, Newstead CG, et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. Transplantation. 2013;96:1082–8. doi: 10.1097/TP.0b013e3182a64db9.
    1. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–67. doi: 10.1111/j.1600-6143.2012.04013.x.
    1. Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S49–55. doi: 10.2215/CJN.03290807.
    1. Wong G, Howard K, Webster A, Chapman JR, Craig JC. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation. 2009;87:1078–91. doi: 10.1097/TP.0b013e31819d32eb.
    1. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–77.
    1. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipient. Am J Transplant. 2003;3:590–8. doi: 10.1034/j.1600-6143.2003.00082.x.
    1. Wu K, Budde K, Lu H, et al. The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Transplantation. 2014;97:1146–54. doi: 10.1097/01.TP.0000441094.32217.05.
    1. Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation. 2001;72:542–4. doi: 10.1097/00007890-200108150-00035.
    1. Zitt E, Woess E, Mayer G, Lhotta K. Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. Transplantation. 2011;92:883–9. doi: 10.1097/TP.0b013e31822d87e8.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren